Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03546829 · ClinicalTrials.gov registry record · Phase 1
Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer
A Phase 1 study of Early Stage Non-Small Cell Lung Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03546829 is a Phase 1 study of Early Stage Non-Small Cell Lung Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03546829, a Phase 1 study of Early Stage Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.
Conditions Studied
Interventions
- DRUG Vancomycin
- RADIATION Precision hypofractionated radiation
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-05 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03546829
The ClinicalTrials.gov registry entry for NCT03546829 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Early Stage Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.
NCT03546829 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03546829 about?
NCT03546829 is a clinical study titled "Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer". The first phase of this study was an open label, randomized pilot study. Enrollment for this phase is now complete. The second phase is a single arm phase 1 safety study. Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression will receive vancomycin for 1 ...
What is the current status of trial NCT03546829?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-03-05. Estimated completion is 2028-12-31.
What conditions does trial NCT03546829 study?
This clinical trial studies the following conditions: Early Stage Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03546829?
The interventions under investigation include: Vancomycin (DRUG), Precision hypofractionated radiation (RADIATION).
Who is sponsoring clinical trial NCT03546829?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03546829 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Early Stage Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.